Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JP Morgan Downgrades Cyteir Therapeutics to Neutral

JP Morgan Downgrades Cyteir Therapeutics to Neutral

JP Morgan analyst Anupam Rama downgrades Cyteir Therapeutics (NASDAQ:CYT) from Overweight to Neutral.

January 20, 2023

1 minute read

JP Morgan analyst Anupam Rama downgrades Cyteir Therapeutics (NASDAQ:CYT) from Overweight to Neutral.

Horizon Therapeutics’ Shares Tumble On Q2 Miss, Trimmed FY22 Outlook

August 3, 11:14 AM

Horizon Therapeutics plc’s (NASDAQ:HZNP) reported Q2 sales of $876.4 million, +5% Y/Y, missing the consensus of $936.10 million. The adjusted…

September 13, 7:01 AM

Raymond James analyst Brian Peterson maintains Braze (NASDAQ:BRZE) with a Outperform and raises the price target from $40 to $50.

October 10, 3:00 PM

Within the last quarter, AerCap Holdings (NYSE:AER) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

October 12, 6:47 AM

Atlantic Equities analyst Kunaal Malde maintains Block (NYSE:SQ) with a Overweight and lowers the price target from $110 to $75.